Redcare Pharmacy Reports Strong Q3 Growth and Reaffirms Full-Year Guidance

Redcare Pharmacy N.V. reported preliminary third-quarter sales figures showing sustained growth across both prescription and non-prescription segments, with total sales increasing 25.2% to EUR 719 million compared to EUR 575 million in the same period last year. The company confirmed all elements of its full-year guidance, indicating confidence in maintaining this positive trajectory through the remainder of 2025.

The strong performance was driven by significant growth in both reporting segments, with DACH markets (Germany, Austria, and Switzerland) achieving 25.2% organic sales growth to EUR 587 million and International markets (Belgium, Italy, France, and the Netherlands) growing 25.4% to EUR 132 million. Year-to-date figures show even more impressive growth, with total sales reaching EUR 2.15 billion, representing a 27% increase compared to the same period in 2024.

Prescription medication sales showed particularly strong momentum, increasing 42.3% to EUR 272 million in the third quarter. The German market led this growth with Rx sales surging 82.1% to EUR 126 million. This performance positions the company to achieve at least EUR 500 million in prescription sales for the full year, a significant milestone for the European e-pharmacy sector. The company's continued expansion in prescription medications reflects the growing acceptance and trust in digital pharmacy services across European markets.

Non-prescription sales maintained steady growth, increasing 16.7% to EUR 448 million in the third quarter. Year-to-date non-Rx sales reached EUR 1.4 billion, up 18% from the previous year. The company's customer base continued to expand, adding 200,000 active customers during the quarter to reach 13.7 million total active customers. Customer satisfaction also improved significantly, with the net promoter score rising to well over 70 compared to 64 in the first half of the year.

CEO Olaf Heinrich commented that the company is delivering strong Q3 momentum, particularly in German prescription sales where the company achieved double-digit quarter-over-quarter growth. He emphasized that growth remains profitable and cash generative, with a solid third-quarter EBITDA performance that has already lifted the year-to-date margin to the company's full-year guidance range of 2 to 2.5%. Management confirmed that financial steering remains fully stable throughout the current transition period, with continuity ensured until the appointment of a new CFO.

The company's performance indicates continued consumer shift toward digital pharmacy solutions across Europe. With the customary seasonal uplift in order volumes expected in the final quarter, Redcare Pharmacy appears well-positioned to maintain its leadership position in the European e-pharmacy market. The company will release its full interim report for the third quarter of 2025 on October 29, 2025, providing more detailed financial information and operational insights. Additional information about the company can be found at https://www.redcare-pharmacy.com.